Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05432622 · ClinicalTrials.gov registry record
A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 95
- Enrollment target
NCT05432622 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 95 participants.
The verdict
NCT05432622 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
Study Summary
The purpose of this study is to examine real-world data among participants with stage IIIa melanoma initiating nivolumab as adjuvant treatment in the community practice setting by utilizing patient data from the United States Oncology Network (USON) iKnowMed (iKM) electronic health records (EHR) database.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2023-07-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05432622
The ClinicalTrials.gov registry entry for NCT05432622 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05432622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05432622 about?
NCT05432622 is a clinical study titled "A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy". The purpose of this study is to examine real-world data among participants with stage IIIa melanoma initiating nivolumab as adjuvant treatment in the community practice setting by utilizing patient data from the United States Oncology Network (USON) iKnowMed (iKM) electronic health records (EHR) dat...
What is the current status of trial NCT05432622?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2019-12-19. Estimated completion is 2023-07-11.
Who is sponsoring clinical trial NCT05432622?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.